Literature DB >> 15234301

The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter.

Sandra M Brown1, Arshad M Khanani, David L McCartney.   

Abstract

PURPOSE: To investigate the effect of daily brimonidine tartrate 0.15% on the dark-adapted pupil diameter.
DESIGN: Observational case series.
METHOD: Ten normal volunteers administered brimonidine to their right eyes once daily. Four to six hours later, infrared pupil photographs were taken after dark adaptation. Measurements were performed at baseline; on treatment days 1, 5, 11, and 18; and on washout days 1 and 2.
RESULTS: One subject had no response. The nine responding subjects showed an average maximum antimydriatic effect of -1.63 mm (range, -0.57 mm--2.30 mm); all subjects experienced tachyphylaxis. Five subjects showed rebound mydriasis (mean maximum rebound +0.87 mm larger than baseline; range 0.50 mm-1.22 mm). The untreated pupil also responded, showing antimydriasis (two subjects), rebound mydriasis (two subjects), or paradoxical direct mydriasis (one subject).
CONCLUSIONS: Once-daily use of brimonidine tartrate to prevent dark-induced pupil dilation can lead to tachyphylaxis and rebound mydriasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234301     DOI: 10.1016/j.ajo.2004.02.017

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

2.  Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.

Authors:  Sung Woo Cho; Joon Mo Kim; Ki Ho Park; Chul Young Choi
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

Review 3.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

4.  Direct and consensual murine pupillary reflex metrics: establishing normative values.

Authors:  Rehana Z Hussain; Steven C Hopkins; Elliot M Frohman; Todd N Eagar; Petra C Cravens; Benjamin M Greenberg; Steven Vernino; Olaf Stüve
Journal:  Auton Neurosci       Date:  2009-08-15       Impact factor: 3.145

Review 5.  Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.

Authors:  Anna D Holmes; Kimberly A Waite; Michael C Chen; Kiruthi Palaniswamy; Thomas H Wiser; Zoe D Draelos; Elyse S Rafal; W Philip Werschler; Alison E Harvey
Journal:  J Clin Aesthet Dermatol       Date:  2015-08

6.  Studying the effect of iris mechanics on the pupillary light reflex using brimonidine-induced anisocoria.

Authors:  Yanjun Chen; Randy H Kardon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

7.  A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.

Authors:  Jay Pepose; Mitchell Brigell; Eliot Lazar; Curtis Heisel; Jonah Yousif; Kavon Rahmani; Ajay Kolli; Min Hwang; Cara Mitrano; Audrey Lazar; Konstantinos Charizanis; Mina Sooch; Marguerite McDonald
Journal:  BMC Ophthalmol       Date:  2022-10-08       Impact factor: 2.086

8.  Quadrant Field Pupillometry Detects Melanopsin Dysfunction in Glaucoma Suspects and Early Glaucoma.

Authors:  Prakash Adhikari; Andrew J Zele; Ravi Thomas; Beatrix Feigl
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.